AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
FDA Gives Green Light To Saphnelo
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.
You may also be interested in...
A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.